Circulating cytokines as predictors of response to immune checkpoint inhibitors (ICIs) in patients (pts) with melanoma (Mel) and non–small cell lung cancer (NSCLC).

• DOI: 10.1200/jco.2022.40.16_suppl.2549
• Publication Date: 2022-06-06T16:03:57Z
• Authors: Giulia Pasello; Aline Sueli Coelh...; Paola Del Bianco; Adolfo Favaretto; Valentina Salizzato; Luisa Piccin; Fable Zustovich; Costanza De Rossi; Jacopo Pigozzo; Alessio Fabozzi; Beatrice Benetti; Laura Tiozzo Fasiolo; Laura Bonanno; Valentina Guarneri; Gian Luca De Salvo; Dario Palleschi; Massimo Gion; Vanna Chiarion-Si...
• Keywords: Clinical endpoint; Univariate analysis

2549 Background: ICIs lead to durable response and a significant survival improvement in limited number of advanced stage Mel NSCLC pts. The identification predictive circulating biomarkers could be promising tool optimize pts’ selection outcome for treatment. Methods: This is prospective real-world study enrolling pts referred four Italian Centers treated with ICIs. primary endpoint verify the presence an association between cytokines (IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, TNFα, GM-CSF) disease control rate (DCR), progression free (PFS) overall (OS). Pts undergo blood collection, before every cycle 6 cycles (T1-T6) at tumor assessment till (PD) or 2 years. Biomarker levels were assessed by Luminex xMAP based technology using R&D High Sensitivity kits. Each marker was categorized according high low maximizing its discriminative ability, tested univariate multiple analyses. Results: We report preliminary results on T1-T2 samples from first 78 enrolled (32 females/46 males; 43 Mel/35 NSCLC; median age 69 years). Serum IL-8 IL-10 significantly higher T1 T2 PD (Kruskal-Wallis test). relative increase (RI) 32% 2% (DC), respectively (p = 0.0001). At logistic analysis, IL-6 RI independent factors predicting probability DC, accuracy 83.8%. associated DC (OR 0.13, 95%CI: 0.03-0.52 OR 0.09, 0.02-0.37, respectively), showed lower 0.14, 0.02-0.58). With follow-up 10.6 months (m), mPFS mOS 5.8 m, 2.3-7.4 8.3 4.0-13.8 6.9 2.8-15.9 12.6 4.7-NE pts, respectively. In Cox model, elevated (HR 3.03, 1.55-6.37, HR 2.86, 1.46-5.63), 1.39-5.94), 4.22, 1.85-11.21) remained worse PFS. Higher 3.85, 1.13-20.0) 4.29, 1.98-9.83) 3.06, 1.43-6.72) OS. Conclusions: serum ICI, combined baseline, are strong predictors PD, PFS, OS, NSCLC. role other tested, their time fluctuations associations clinical prognostic factors, gender, immuno-related adverse events will presented meeting.